Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty

 

PDF Download Buy Article Permissions and Reprints

Summary

Tissue factor (TF) is present in small quantities in normal blood and is reported to be elevated in arterial and venous thrombosis. Patients undergoing total knee arthoplasty (TKA) are at high risk of post-operative venous thromboembolism (VTE). To evaluate the possible contribution of elevated blood TF to VTE risk, we performed serial studies of peripheral blood mononuclear cell (PBMC) functional TF procoagulant activity (PCA) in 19 patients after TKA. PBMC and platelet TF PCA were measured by a functional, clot-based assay following decryption with a calcium ionophore. Plasma TF antigen levels were measured by ELISA. All subjects received chemoprophylaxis and none had VTE. After TKA total TF PCA of PBMC was elevated in 19 of 19 subjects. The peak increase above preoperative levels was 1. 1–13.6 fold (>two-fold in 58% and >three-fold in 42%). Median TF PCA of PBMC was not elevated following tourniquet removal, but it was significantly elevated on postoperative days 1 and 2. Thereafter, it decreased to near preoperative values at day 6. Neither platelet TF PCA nor plasma TF antigen levels increased significantly. Since the PBMC count did not rise, the increase in TF PCA was attributable to cell synthesis. The increase in blood TF PCA preceded the median time of diagnosis of venous thromboembolism after TKA established previously. These observations indicate a) TKA stimulates synthesis of encrypted PBMC TF PCA which is likely to contribute to the pathophysiology of VTE; b) TF antigen is not a reliable indicator of TF PCA.

• References

• 1 Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87: 6934-6938.
  CrossrefPubMedGoogle Scholar
• 2 Eilertsen KE, Østerud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004; 15: 521-538.
  PubMedGoogle Scholar
• 3 Giesen PLA, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT. et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
  CrossrefPubMedGoogle Scholar
• 4 Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770.
  CrossrefPubMedGoogle Scholar
• 5 Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-461.
  PubMedGoogle Scholar
• 6 Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731.
  CrossrefPubMedGoogle Scholar
• 8 Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 05: 520-527.
  CrossrefPubMedGoogle Scholar
• 9 Gentile NT, Vaidyula VR, Kanamalla U, DeAngelis M, Gaughan J, Rao AK. Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: Impact of hypergylcemia. Thromb Haemost 2007; 98: 1007-1013.
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Kamikura Y, Wada H, Nobori T, Kobayashi T, Sase T, Nishikawa M. et al. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res 2005; 116: 307-312.
  CrossrefPubMedGoogle Scholar
• 11 Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R. et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007; 05: 475-482.
  CrossrefPubMedGoogle Scholar
• 12 Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, Wilhite DB. et al. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006; 96: 738-743.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Vieira LM, Dusse LMS, Fernandes AP, MartinsFilho OA, de Bastos M, Ferreira MFR. et al. Monocytes and plasma tissue factor levels in normal individuals and patients with deep venous thrombosis of the lower limbs: potential diagnostic tools?. Thromb Res 2007; 119: 157-165.
  CrossrefPubMedGoogle Scholar
• 14 Huisse MG, Ajzenberg N, Feldman L, Guillin MC, Steg PG. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost 2009; 101: 734-740.
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK. et al. Prothrombotic activity is associated with the anatomical as well as the functional severity of peripheral arterial occlusive disease. Thromb Haemost 2006; 95: 702-707.
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factor. J Thromb Haemost 2006; 04: 1747-1755.
  CrossrefPubMedGoogle Scholar
• 17 Maly M, Hrachovinova I, Tomasov P, Salaj P, Hajek P, Veselka J. Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but normal concentration of tissue factor antigen in platelet free plasma – a pilot study. Eur J Haematol 2008; 82: 148-153.
  PubMedGoogle Scholar
• 18 Del Turco S, Basta G, Lazzerini G, Evangelista M, Rainaldi G, Tanganelli P. et al. Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica 2008; 93: 892-899.
  CrossrefPubMedGoogle Scholar
• 19 Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyöngyösi M, Sperker W. et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherocsclerotic plaque. Blood 2002; 99: 2794-2800.
  CrossrefPubMedGoogle Scholar
• 20 Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, López JA. Microvesicle-associated tissue factor and Trousseau’s syndrome. J Thromb Haemost 2007; 05: 70-74.
  CrossrefPubMedGoogle Scholar
• 21 Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariëns RAS. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113: 537-543.
  CrossrefPubMedGoogle Scholar
• 22 Dahm A, Rosendaal FR, Andersen TO, Sandset PM. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state. Br J Haematol 2006; 132: 333-338.
  CrossrefPubMedGoogle Scholar
• 23 Morrow DA, Murphy SA, McCabe CH, Mackman N, Wong HC, Antman EM. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 Trial. Eur Heart J 2005; 26: 682-688.
  CrossrefPubMedGoogle Scholar
• 24 Lee A, Agnelli G, Büller H, Ginsberg J, Heit J, Rote W. et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-78.
  CrossrefPubMedGoogle Scholar
• 25 Himber J, Wohlgensinger C, Roux S, Damico LA, Fallon JT, Kirchhofer D. et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 2003; 01: 889-895.
  CrossrefPubMedGoogle Scholar
• 26 Szalony JA, Suleymanov OD, Salyers AK, Panzer-Knodle SG, Blom JD, LaChance RM. et al. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. Thromb Res 2003; 112: 167-174.
  CrossrefPubMedGoogle Scholar
• 27 Colwell Jr. CW, Hardwick ME. Rationale for lowmolecular-weight heparin prophylaxis after total knee arthroplasty. Clin Orthop Relat Res 2006; 452: 181-185.
  CrossrefPubMedGoogle Scholar
• 28 Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8th Edition). Chest 2008; 133: 381S-453S.
  CrossrefPubMedGoogle Scholar
• 29 Kageyama K, Nakajima Y, Shibasaki M, Hashimoto S, Mizobe T. Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty. J Thromb Haemost 2007; 05: 738-745.
  CrossrefPubMedGoogle Scholar
• 30 Bach RR, Johnson GJ, Long JR, Key NS. Intravascular tissue factor procoagulant activity increases following joint replacement surgery. J Thromb Haemost 2003; 01 (Suppl. 01) P0536
  PubMedGoogle Scholar
• 31 Henriksson CE, Klingenberg O, Ovstebo R, Joo GB, Westvik AB, Kierulf P. Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost 2005; 94: 1236-1244.
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-4020.
  CrossrefPubMedGoogle Scholar
• 33 Carson SD, Ross SE, Bach RR, Guha A. An inhibitory monoclonal against human tissue factor. Blood 1987; 70: 490-493.
  PubMedGoogle Scholar
• 34 Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA. et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-4223.
  PubMedGoogle Scholar
• 35 Osterud B, Due Jr. J. Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes. Scand J Haematol 1984; 32: 258-264.
  PubMedGoogle Scholar
• 36 Chung J, Tabuchi N, Koyama T. The increase in tissue factor-bearing leukocytes after off-pump coronary artery bypass surgery. Thromb Haemost 2008; 100: 952-954.
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-1531.
  CrossrefPubMedGoogle Scholar
• 38 Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner Jr. GA. et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001; 83-A: 336-345.
  PubMedGoogle Scholar
• 39 Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L’Espérance B, Demers C. et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124: 619-626.
  CrossrefPubMedGoogle Scholar
• 40 Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 1687-1693.
  CrossrefPubMedGoogle Scholar
• 41 Del Turco S, Basta G, Lazzerini G, Evangelista M, Rainaldi G, Tanganelli P. et al. Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica 2008; 93: 892-899.
  CrossrefPubMedGoogle Scholar
• 42 Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S. et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 87: 343-347.
  CrossrefPubMedGoogle Scholar
• 43 Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nature Med 2003; 09: 458-462.
  CrossrefPubMedGoogle Scholar
• 44 Bogdanov VY, Kirk RI, Miller C, Hathcock JJ, Vele S, Gazdoiu M. et al. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 2006; 04: 158-167.
  PubMedGoogle Scholar
• 45 Censarek P, Bobbe A, Grandoch M, Schrör K, Weber A-A. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost 2007; 97: 11-14.
  Article in Thieme ConnectPubMedGoogle Scholar
• 46 Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M. et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007; 120 (Suppl. 02) S13-S21.
  CrossrefPubMedGoogle Scholar
• 47 Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96: 1233-1239.
  CrossrefPubMedGoogle Scholar
• 48 Levine SJ. Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 2008; 283: 14177-14181.
  CrossrefPubMedGoogle Scholar
• 49 He Y, Chang G, Zhan S, Song X, Wang X, Luo Y. Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. Biochem Biophys Res Comm 2008; 370: 489-494.
  CrossrefPubMedGoogle Scholar